

A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases

NCT06512883

Status	RECRUITING
Phase	Phase 3
Sponsor	AstraZeneca
Enrollment	14 participants

Key Eligibility Criteria

Inclusion (11)

- All Cohorts:
 - Male or female participants must be aged 6 to < 18 years of age at the time of signing the assent form and their caregiver signing the informed consent form.
 - Body weight greater than (\geq) 15 kilograms (kg).
 - EGPA Cohort:
 - Therapy with corticosteroids: The prescribed dose of oral corticosteroids (OCS) (greater than $>$ 0.1 milligrams per kilogram per day (mg/kg/day), max dose of 50 milligrams per day (mg/day) must be stable (that is, no adjustment of the dose) for at least 4 weeks prior to baseline (Visit 2).
- ... and 6 more (see full listing online)

Exclusion (13)

- All Cohorts:
 - Any current malignancy or history of malignancy.
 - History of anaphylaxis to any biologic therapy or vaccine.
 - Known, pre-existing, clinically significant endocrine, autoimmune, metabolic, neurological, renal, gastrointestinal, hepatic, haematological, respiratory, or any other system abnormalities.
 - Previous receipt of benralizumab in an interventional clinical study.
- ... and 8 more (see full listing online)

Locations (13 total)

Research Site, Aurora, Colorado, United States
Research Site, Cincinnati, Ohio, United States
Research Site, Highland Hills, Ohio, United States
... and 10 more locations

<https://clinicaltrials.gov/study/NCT06512883>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.